Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Therapeutic area

Respiratory, thoracic and mediastinal disorders – page 93

  • 1 291 clinical trials
  • 445 recruiting
  • 379 conditions
  • 29 countries

Conditions in this area

379 conditions with trials, the busiest first

Non-small cell lung cancer332Asthma89Non-small cell lung cancer metastatic82Chronic obstructive pulmonary disease60Non-small cell lung cancer stage IV59Pulmonary arterial hypertension41COVID-1939Non-small cell lung cancer stage III37Idiopathic pulmonary fibrosis34Small cell lung cancer33Pneumonia32Non-small cell lung cancer stage IIIB31Small cell lung cancer extensive stage31Influenza29Interstitial lung disease29Lung neoplasm malignant29Cystic fibrosis24Pulmonary hypertension24Conjunctivitis allergic23Chronic rhinosinusitis with nasal polyps21Respiratory syncytial virus infection20Rhinitis allergic20Post-acute COVID-19 syndrome19Ovarian cancer18+355

Clinical trials in Respiratory, thoracic and mediastinal disorders

1 291 trials across Europe, recruiting first

Type of trial
Recruitment status
Quick filters

1 291 clinical trials

Non-small cell lung cancer+2

Not recruiting

Study Comparing Lorlatinib and Crizotinib for Patients with Advanced ALK-Positive Non-Small Cell Lung Cancer

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years
  • Substances:Lorlatinib
  • Sponsor:Pfizer Inc.

Non-small cell lung cancer

Not recruiting

Study of Nivolumab and Relatlimab for Patients with Resectable Non-Small Cell Lung Cancer

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Nivolumab
  • Sponsor:Universitaetsklinikum Essen AöR

Pulmonary hypertension

Not recruiting

Study on the Long-term Safety and Efficacy of Ralinepag for Patients with Pulmonary Arterial Hypertension

InvestigationalNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Ralinepag
  • Sponsor:United Therapeutics Corp.

Asthma

Not recruiting

Study Comparing Depemokimab, Mepolizumab, and Benralizumab for Adults and Adolescents with Severe Eosinophilic Asthma

Registered drug
Countries:AustriaAustria
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Benralizumab
  • Sponsor:Glaxosmithkline Research & Development Limited

Pulmonary arterial hypertension

Not recruiting

Study on Treprostinil Palmitil Inhalation Powder for Patients with Pulmonary Arterial Hypertension

Investigational
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Treprostinil Palmitil
  • Sponsor:Insmed Inc.

Non-small cell lung cancer+4

Not recruiting

Study on the Effectiveness and Safety of Osimertinib for Patients with Stage IB-IIIA Non-Small Cell Lung Cancer After Tumor Removal

Registered drug
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Osimertinib
  • Sponsor:AstraZeneca AB

Non-small cell lung cancer

Not recruiting

Study on Afatinib and Osimertinib for Patients with EGFR-Mutated, T790M Negative Non-Squamous Non-Small Cell Lung Cancer in First-Line Treatment

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Afatinib
  • Sponsor:Universitaetsmedizin der Johannes Gutenberg-Universitaet Mainz KöR

Non-small cell lung cancer+2

Not recruiting

Study on the Safety of Osimertinib with Radiation for Patients with Stage IV EGFR-Mutation Positive Non-Small Cell Lung Cancer

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Osimertinib
  • Sponsor:AIO-Studien gGmbH

COVID-19

Not recruiting

Study of nirmatrelvir and ritonavir (Paxlovid) for prevention of long COVID-19 in patients with acute COVID-19 infection in Norway

Registered drug
Countries:NorwayNorway
  • Participants:18–64 years
  • Substances:Nirmatrelvir
  • Sponsor:Helse Bergen HF

Non-small cell lung cancer

Not recruiting

Study on the Effects of Pembrolizumab, Atezolizumab, and Nivolumab in Patients with Advanced Non-Small Cell Lung Cancer

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Atezolizumab
  • Sponsor:Institut Bergonie

Non-small cell lung cancer

Not recruiting

Study of MK-2870 and Chemotherapy for Patients with Advanced EGFR-Mutated Non-Small Cell Lung Cancer

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:Merck Sharp & Dohme LLC

Asthma

Not recruiting

Study on Benralizumab for Patients with Severe Asthma

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Benralizumab
  • Sponsor:Centre Hospitalier Universitaire De Nantes

Substances studied in this area

The therapies tested most often in Respiratory, thoracic and mediastinal disorders trials.

Carboplatin174 clinical trialsPembrolizumab149 clinical trialsCisplatin132 clinical trialsPemetrexed112 clinical trialsPaclitaxel83 clinical trialsDurvalumab71 clinical trialsAtezolizumab53 clinical trialsNivolumab50 clinical trialsSodium Chloride49 clinical trials
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.